Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,025 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Positive Phase 3 data for bepirovirsen
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the London Stock Exchange’s Regulatory News Service (RNS) announcing clinical trial data and associated forward-looking statements. It does not contain financial statements, corporate governance materials, shareholder votes, or management/board changes. It is not an earnings release, annual or interim report but a general regulatory announcement. Therefore it falls under the Regulatory Filings category (RNS).
2026-05-28 English
POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN
Regulatory Filings
2026-05-28 English
Director/PDMR Shareholding
Director's Dealing Classification · 92% confidence The document is an RNS announcement detailing an insider transaction by a person discharging managerial responsibilities (PDMR) – Maya Martinez-Davis – involving acquisition of ADS under her GSK savings plan. This matches the definition of a Director’s Dealing (insider share transaction) notification.
2026-05-27 English
DIRECTOR/PDMR SHAREHOLDING
Regulatory Filings
2026-05-27 English
SPECIALIZED DISCLOSURE REPORT
Regulatory Filings
2026-05-26 English
Admission to Trading
Share Issue/Capital Change Classification · 90% confidence The document is an RNS announcement by GSK plc notifying the market that additional ordinary shares have been admitted to trading under an existing block listing admission (Share Save Plan). It provides ISIN, number of shares admitted, total securities, and other details specific to a new share issuance admission. This matches the “Share Issue/Capital Change” category (SHA).
2026-05-26 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.